我要投票 朗迪Reneed在补钙行业中的票数:224
· 外 推 电 报 ·
2025-02-27 01:46:21 星期四

【朗迪Reneed是哪个国家的品牌?】

朗迪Reneed是什么牌子?「朗迪Reneed」是 北京振东康远制药有限公司 旗下著名品牌。该品牌发源于北京市,由创始人李昆在2003-11-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力朗迪Reneed品牌出海!通过在本页面挂载朗迪Reneed品牌的产品链接和联系邮箱,可以提高朗迪Reneed产品曝光!跨境电商爆单神器,目前只要100元/年哦~

钙营养补充剂品牌,主打维生素矿物质钙补充剂类药物,集研发、生产、销售于一体的集团化现代综合制药企业


北京振东康远制药有限公司始建于2003年10月,是国内较大的具有自主品牌的维生素矿物质钙补充剂类药物生产企业,是一家集研发、生产、销售于一体的集团化现代综合制药公司,是中国补钙药物的佼佼者和先锋。公司产品遍布全国,公司“朗迪”牌碳酸钙D3片(II)和碳酸钙D3颗粒已成为中国钙补充剂类药品市场的主流。公司2015年与上市公司振东集团山西振东制药股份有限公司强强联合,完成重大重组,实现了跨跃式发展。

公司于2009年进入中国钙制剂市场,旗下现有7家直属或控股的制药公司、2家直属药物研发公司及多家医药贸易公司,在30多个城市设立了办事机构,有数千家合作伙伴,累计总投资超过10亿元,全国有数千名员工为康远工作。

公司位于北京市昌平区西部约15公里的北京市昌平区流村工业园内,隶属中关村科技园昌平园。该厂区自2012年开始建造,总投资近亿元,按照新版欧盟GMP标准及中国GMP标准进行规划、设计和建设施工,配有国际前沿的制粒、干燥、混合、压片、包装等片剂、硬胶囊剂、颗粒剂生产线及软胶囊剂生产线,该项目已于2014年通过了BFDA组织的GMP认证,并获得片剂、硬胶囊剂、颗粒剂、软胶囊剂GMP证书。项目年生产能力近百亿片(粒、袋)。该项目的建成使康远制药一跃成为国内维生素矿物质钙补充剂类药物较大生产企业。

公司发展过程中始终以“构建国人健康骨骼”为已任,以“树民族工业品牌,为中国制药争光”为使命,为中国钙制剂的发展做出了较大的贡献,大大改善了亿万国人的生活质量。康远人负有共同的使命,遵循一致的价值观,始终秉承“济世安康、立勋鸿远”宗旨来服务社会、回报社会。目前公司年营业收入达数十亿元,年上缴税金数亿元。随着公司高速发展和对未来中国经济和全球钙制剂市场发展前景充分信心,北京振东康远制药正不断加快创新、运筹帷幄、酝酿百年规划,未来的康远终将成为一家拥有精良技术和设备、管理成熟的世界制药公司。


英文翻译:Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd., a brand of calcium supplements, is a group modern comprehensive pharmaceutical enterprise integrating R & D, production and sales. It was founded in October 2003. It is a large domestic manufacturer of vitamin and mineral calcium supplements with its own brand, integrating R & D, production and sales Group modern comprehensive pharmaceutical company is the leader and pioneer of calcium supplements in China. The company's products are all over the country, and its "landi" brand calcium carbonate D3 tablets (II) and calcium carbonate D3 particles have become the mainstream of China's calcium supplements market. In 2015, the company and the listed company Zhendong Group Shanxi Zhendong Pharmaceutical Co., Ltd. jointly completed major restructuring and achieved a leap forward development. In 2009, the company entered the calcium preparation market in China. At present, it has 7 pharmaceutical companies directly under or controlled by the company, 2 pharmaceutical research and development companies directly under the company and many pharmaceutical trading companies. It has set up offices in more than 30 cities, thousands of partners, with a total investment of more than 1 billion yuan, and thousands of employees working for Kangyuan. The company is located in Liucun Industrial Park, Changping District, Beijing, about 15km away from the west of Changping District, Beijing. The plant has been constructed since 2012, with a total investment of nearly 100 million yuan. It is planned, designed and constructed in accordance with the new version of EU GMP standard and China GMP standard. It is equipped with internationally cutting-edge tablet, hard capsule, granule production line and soft capsule production line. The project has passed the GMP certification organized by bfda in 2014, and has obtained tablet GMP certificate of hard capsule, granule and soft capsule. The annual production capacity of the project is nearly 10 billion pieces (grain and bag). With the completion of the project, Kangyuan pharmaceutical has become a large domestic manufacturer of vitamin, mineral and calcium supplements. In the development process of the company, we always take "building healthy skeleton of Chinese people" as our responsibility, take "building national industrial brand, winning honor for Chinese pharmaceutical" as our mission, and have made great contribution to the development of Chinese calcium preparation, greatly improving the quality of life of hundreds of millions of Chinese people. Kangyuan people have a common mission, follow the same values, and always adhere to the tenet of "helping the world and health, and making contributions to Hongyuan" to serve and repay the society. At present, the company's annual operating revenue is billions of yuan, and the annual tax payment is hundreds of millions of yuan. With the rapid development of the company and full confidence in the future development of China's economy and the global calcium preparation market, Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd. is constantly accelerating innovation, strategizing and brewing a hundred year plan. In the future, Kangyuan will eventually become a world pharmaceutical company with excellent technology and equipment and well managed.

本文链接: https://www.waitui.com/brand/52bc17e3b.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

美股大型科技股盘前多数上涨,英伟达涨超2%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,英伟达涨超2%,特斯拉涨超1%,亚马逊涨0.9%,Meta涨0.84%,谷歌涨0.6%,微软涨0.37%,奈飞涨0.15%;苹果跌0.31%。

2小时前

热门中概股美股盘前普涨,理想汽车涨超9%

36氪获悉,热门中概股美股盘前普涨,截至发稿,理想汽车涨超9%,小鹏汽车涨超8%,京东涨超7%,阿里巴巴、爱奇艺涨超4%,拼多多、微博涨超3%,百度、网易、蔚来涨超2%。

2小时前

美国抵押贷款利率降至6.88%,创今年以来最低水平

美国抵押贷款利率上周降至今年以来的最低水平,但不足以刺激贷款活动反弹。美国抵押贷款银行家协会(MBA)周三公布的数据显示,截至2月21日当周,30年期抵押贷款的合约利率下降5个基点,至6.88%。抵押贷款利率跟随美国国债收益率,过去一周美债收益率下行,因为投资者在股票和原油石油遭遇抛售之际寻求避险。经济数据也导致近期收益率下降,这些数据包括1月份零售销售疲软、消费者对长期通胀率的预期升至1995年以来最高。(财联社)

2小时前

巴奴火锅门店数量已超140家,创始人称上市是未来重要方向

日前,巴奴创始人杜中兵表示,部分消费者认为巴奴的价格偏高,未来我们将披露财务报表,让消费者更清晰地了解巴奴产品的价值。截至去年底,巴奴毛肚火锅已经在全国开设了超过140家直营门店,综合净利润率为9%,平均翻台率约为3.7次。上市也是巴奴火锅未来重要发展方向。(证券时报)

2小时前

宗申动力:西藏国隆科技拟减持公司不超3%股份

36氪获悉,宗申动力发布公告,持股18.11%的股东西藏国隆科技有限公司计划以集中竞价方式和大宗交易方式,减持公司股份不超过3435.08万股(占公司总股本的3%)。公司董事李耀计划以集中竞价方式减持公司股份不超过4.24万股(占公司总股本的0.0037%)。

2小时前

本页详细列出关于Schiff旭福的品牌信息,含品牌所属公司介绍,Schiff旭福所处行业的品牌地位及优势。
咨询